drug induced hepatits. Toxic liver disease with hepatic necrosis
Conditions
Interventions
Intervention 1: in case group patients take anti TB drugs and 600 mg / BID of n-acetyl cystein for one month. Intervention 2: in control group patients take anti-tb drugs and 600 mg / BID of placebo f
Prevention
Placebo
in case group patients take anti TB drugs and 600 mg / BID of n-acetyl cystein for one month
in control group patients take anti-tb drugs and 600 mg / BID of placebo for one month
Sponsors
Arak University of Medical sciences
Eligibility
Sex/Gender
All
Age
50 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age over 50 years; hemodynamic stability (mean arterial blood pressure >70 mmHg or systolic blood pressure >90mmHg ) Exclusion criteria: history of acute or chronic renal and liver failure accordance with the definitions of relevant, Unavailability of information related to liver function in basic mode, use of N- acetylcysteine orally, injected or inhaled during 1 month before the beginning of the study; Experience has confirmed that the incidence of hypersensitivity reactions following oral, intravenous or inhaled N- acetylcysteine; receiving concomitant drugs or compounds with antioxidant effects such as vitamin C, vitamin E; HIV + patients; use of alcohol
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver enzym and if necessary bilirubin. Timepoint: start of treatment and end of first , second, third and fourth of treatment. Method of measurement: paraclinic measurement and clinical interview. | — |
Secondary
| Measure | Time frame |
|---|---|
| Decrease of ESR and CRP. Timepoint: start of tretment and end of first , second,third , fourth of tretment. Method of measurement: lESR and CRP measurement. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.aliasghar farazi
Arak University of Medical Sciences
Outcome results
None listed